Electromyography ; Humans ; Occupational Health

Objective:To investigate the risk factors of preterm premature ruPture of membrane(PPROM) and their pregnancy outcomes.Methods:The clinical data of 95 cases of patients with PPROM admitted and treated in our hospital from October 2013 to July 2016 were collected,which were divided into two groups,observation group(gestational week 28-33 +6 weeks) and control group(gestational week 34-36 +6 weeks).The risk factors of PPROM,delivery method and pregnancy outcomes were analyzed.Results:Genital tract infection was the main risk factor of PPROM(33.68％).of the incidences of cesarean delivery,neonatal asphyxia,neonatal infections and neonatal death in observation group were significantly higher than those of control group,the differences were statistically significant(P ＜ 0.05).The intrauterine infection and puerperal infection rates of observation group of were higher than those of control group,but differences were not statistically significant (P ＞ 0.05).Conclusions:Reproductive tract infections is the most important risk factor of PPROM.The purpose of active treatment including tocolytic therapy and prevention of infection for the patients with PPROM less than 34 weeks is to prolong the gestational weeks,to reduce the rate of neonatal complication,and to improve the pregnancy outcome.

Objective:To study the expression of Pleiotrophin and Midkine protein in endometrium of endometriosis and its clinical significance.Methods:Expressions of Pleiotrophin and Midkine protein were examined by immunohistochemical staining method in 30 endometrial samples of endometriosis(study group) and 29 endometrium of uterine fibroid(control group).Result:Pleiotrophin protein mainly expressed in the membrane and plasma of glandular epithelium of endometrium.Midkine protein mainly expressed in the plasma of grandular epithelium of endometrium and expressed in nuclei in some samples.The expression of Pleiotrophin and Midkine protein in endometriosis was significantly higher than that in the control group(P

Aging ; Arteriosclerosis ; pathology ; Blood Vessels ; pathology ; Cellular Senescence ; Humans ; Medicine, Chinese Traditional

Diabetes Mellitus, Type 2 ; drug therapy ; Humans ; Hypoglycemic Agents ; therapeutic use ; Non-alcoholic Fatty Liver Disease ; drug therapy

Choroidal neovascularization( CNV) is a common severe complication of ocular fundus diseases, with great potentiality to cause blindness. The treatments of CNV include photodynamic therapy ( PDT ) and anti-vascular endothelial growth factor( VEGF) therapy. However, PDT produces little visual benefits, and may result in ischemia, inflammatory responses, even the secondary expressions of VEGF. Anti-VEGF therapy sustained visual efficiency by repeated injections, causing economic burden and adverse effects related to injection. Recently, PDT combined with anti-VEGF therapy has progressed in laboratory and clinical research. Therefore, the combined modality therapy became one of the treatment options for CNV. In order to reduce the side effects of mono -therapy, further study is required to determine appropriate combinations and dosage.

Objective:To investigate the effect of levosimendan on myocardial injury in patients with sepsis.Methods:Eighty-two patients with sepsis complicated by myocardial injury who received treatment in Yinzhou Second Hospital from June 2015 to September 2017 were included in this study. They were randomly assigned to receive either dobutamine treatment (control group, n = 41) or levosimendan treatment (study group, n = 41) based on conventional basic treatment. Before and after treatment, serum levels of heart-type fatty acid-binding protein (H-FABP), cardiac troponin I (cTnI), N-terminal pro brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LEVF), Acute Physiology, Age, and Chronic Health Evaluation II (APACHE II) score, intensive care unit (ICU) stay, and 28-day mortality were compared between the control and study groups. Results:Before treatment, there were no significant differences in serum levels of H-FABP, cTnI, and NT-proBNP as well as LVEF and APACHE II score between the control and study groups (all P > 0.05). At 6 hours after treatment, serum levels of H-FABP, cTnI, and NT-proBNP in the control and study groups [(26.22 ± 7.22) μg/L vs. (39.93 ± 9.85) μg/L, (25.97 ± 6.93) μg/L vs. (34.86 ± 8.55) μg/L, (0.004 ± 0.002) μg/L vs. (1.580 ± 0.360) μg/L, (0.003 ± 0.003) μg/L vs. (0.760 ± 0.210) μg/L, (1 561.73 ± 633.70) ng/L vs. (2 570.06 ± 747.95) ng/L, (1 602.28 ± 681.45) ng/L vs. (2 225.53 ± 585.14) ng/L] were significantly increased compared with before treatment ( t = 7.188, 5.172, 28.031, 23.079, 6.586, 4.443, all P < 0.05). After treatment, serum levels of H-FABP, cTnI, and NT-proBNP in the study group were significantly lower than those in the control group ( t = 2.489, 12.598, 2.323, all P < 0.05). In each group, serum level of H-FABP at 72 hours after treatment was significantly lower than that at 6 hours after treatment [(39.93 ± 9.85) μg/L vs. (6.28 ± 1.07) μg/L, (34.86 ± 8.55) μg/L vs. (5.82 ± 1.88) μg/L], serum levels of cTnI and NT-proBNP at 72 hours after treatment were significantly increased compared with those at 6 hours after treatment [(1.58 ± 0.36) μg/L vs. (2.72 ± 0.55) μg/L, (0.76 ± 0.21) μg/L vs. (1.78 ± 0.49) μg/L, (2 570.06 ± 747.95 ) ng/L vs. (3 623.27 ± 1 105.28) ng/L, (2 225.53 ± 585.14) ng/L vs. (3 128.08 ± 1 098.07) ng/L, t = 11.105, 12.251, 5.053, 4.645, all P < 0.05). At 72 hours after treatment, serum levels of cTnI and NT-proBNP levels in the control group were significantly higher than those in the study group ( t = 8.171, 2.035, both P < 0.05). At 72 hours after treatment, there was no significant difference in serum H-FABP level between the control and study groups ( P > 0.05). At 72 hours after treatment, APACHE II score in each group was significantly decreased and LVEF in each group was significantly increased compared with before treatment ( t = 7.718, 11.380, 9.049, 9.501, all P < 0.05). The change in APACHE II score at 72 hours after treatment relative to before treatment in the study group was more obvious than that in the control group ( t = 2.583, P < 0.05). At 72 hours after treatment, there were no significant differences in LVEF, ICU stay and 28-day mortality between the control and study groups (all P > 0.05). Conclusion:Levosimendan can reduce the serum levels of H-FABP, cTnI and NT-proBNP as well as APACHE II score in patients with sepsis, increase serum level of LVEF, and alleviate myocardial injury.

Objective To observe the clinical efficacy of tongue acupuncture plus balloon dilatation in treating deglutition disorders due to achalasia of the cricopharyngeus muscle after cerebral stroke.Method Forty-eight patients with deglutition disorders due to achalasia of the cricopharyngeus muscle after cerebral stroke were randomized into a treatment group and a control group, 24 cases each. The two groups both received conventional rehabilitation training. In addition, the treatment group was given tongue acupuncture plus balloon dilatation, and the control group was by balloon dilatation alone. The two groups were treated once a day, for a total of 4 weeks. The water drinking test score and Standardized Swallowing Assessment (SSA) were evaluated before and after the treatment.Result The water drinking test and SSA scores were significantly changed after the intervention in both groups (P<0.05). After the treatment, the water drinking test and SSA scores in the treatment group were significantly different from those in the control group (P<0.05).Conclusion Tongue needling plus balloon dilatation is an effective approach in treating deglutition disorders due to achalasia of the cricopharyngeus muscle after cerebral stroke.

OBJECTIVE:To prepare zolmitriptan-diclofenac microemulsion,and conduct quality evaluation and in vitro trans-dermal study. METHODS:Using solubility and microemulsion area in pseudo-ternary phase diagram as indexes,the types of oil phase and mixed emulsifier ratio of zolmitriptan-diclofenac microemulsion were screened;the microemulsion quality was inspected using particle size,Zeta potential,appearance and stability. HPLC was used to measure the contents of zolmitriptan and diclofenac. Transdermal diffusion test instrument was used,2 g microemulsion was smeared in cuticle of extracouporeal rats'skin,and cumula-tive transdermal rate in 24 h was determined. RESULTS:The microemulsion formulation was as follow as 10% oil phase(octanoic acid triglyceride),25% mixture emulgator [polysorbate 80-brij 97 (1:1)],8.3% propylene glycol and 25 mg zolmitriptan,1.25 mg diclofenac,and water adding to 100 mL. The average particle size of prepared microemulsion was(28.2±2.5)nm,Zeta poten-tial was(-3.25±0.33)mV,the appearance was rounding;the microemulsion showed no stratification or flocculation at room tem-perature after placed for 1 month. Contents of zolmitriptan and diclofenac were 0.248 mg/mL,12.46 mg/mL(n=3);24 h cumula-tive transdermal rates were 80%,75%. CONCLUSIONS:Zolmitriptan-diclofenac microemulsion is prepared,and its in vitro trans-dermal ability is good.

Nonunion or delayed union remains one of the major complicatio ns of fractures. Repair of fractures involves a sequence of dynamic events which ultimately restore the integrity of bone and its biomechanical properties, incl uding such methods as surgery, internal fixation, bone grafting, external fixati on, electrical stimulation, ultrasound, and high-energy extracorporeal shock wa ve. The preferred management of nonunion and delayed union is autologous bone gr afting. However, the supply of suitable bone is limited and it often results in additional morbidity to the donor site. Recently some advances have been made in the therapeutic principle for nonunion or delayed union. It is aimed at providi ng non-invasion, less complication, and safe treatment. This article introduces the development of some effective and safe therapies for nonunion or delayed un ion.